|
apoptotic process involved in development
|
GO_1902742 |
[Any apoptotic process that is involved in anatomical structure development.] |
|
Mad-Max complex
|
GO_0070443 |
[A transcriptional repressor complex that consists of a heterodimer of the bHLH-ZIP proteins Mad and Max.] |
|
oligodendrocyte progenitor proliferation
|
GO_0070444 |
[The multiplication or reproduction of oligodendrocyte progenitor cells by cell division, resulting in the expansion of their population. Oligodendrocyte progenitors give rise to oligodendrocytes, which form the insulating myelin sheath of axons in the central nervous system.] |
|
fusome organization
|
GO_0045478 |
[A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the fusome, a large intracellular spectrin-rich structure found in insect germline cells and mammalian hematopoietic cells.] |
|
regulation of oligodendrocyte progenitor proliferation
|
GO_0070445 |
[Any process that modulates the frequency, rate or extent of oligodendrocyte progenitor proliferation.] |
|
vesicle targeting to fusome
|
GO_0045479 |
[The recruitment of vesicles to the fusome. The vesicles become the fusome tubule network and are necessary for the assembly of the fusome.] |
|
negative regulation of oligodendrocyte progenitor proliferation
|
GO_0070446 |
[Any process that stops or decreases the rate or extent of oligodendrocyte progenitor proliferation.] |
|
positive regulation of oligodendrocyte progenitor proliferation
|
GO_0070447 |
[Any process that activates or increases the rate or extent of oligodendrocyte progenitor proliferation.] |
|
laricitrin 5'-O-methyltransferase activity
|
GO_0070448 |
[Catalysis of the reaction: S-adenosyl-L-methionine + laricitrin = S-adenosyl-L-homocysteine + syringetin.] |
|
elongin complex
|
GO_0070449 |
[A transcription elongation factor complex that suppresses RNA polymerase II pausing, and may act by promoting proper alignment of the 3'-end of nascent transcripts with the polymerase catalytic site. Consists of a transcriptionally active Elongin A subunit (about 100 kDa) and two smaller Elongin B (about 18 kDa) and Elongin C (about 15 kDa) subunits.] |
|
R8 cell-mediated photoreceptor organization
|
GO_0045470 |
[The regionalization process that coordinates the recruitment and organization of other non-R8 photoreceptors by the R8 photoreceptor.] |
|
response to ethanol
|
GO_0045471 |
[Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an ethanol stimulus.] |
|
positive regulation of nucleotide-binding oligomerization domain containing 1 signaling pathway
|
GO_0070430 |
[Any process that activates or increases the frequency, rate, or extent of the nucleotide-binding oligomerization domain containing 1 (NOD1) pathway.] |
|
positive regulation of nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway
|
GO_0070426 |
[Any process that activates or increases the frequency, rate, or extent of a nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway (NLR) pathway.] |
|
regulation of nucleotide-binding oligomerization domain containing 1 signaling pathway
|
GO_0070428 |
[Any process that modulates the frequency, rate, or extent of the nucleotide-binding oligomerization domain containing 1 (NOD1) pathway.] |
|
nucleotide-binding oligomerization domain containing 2 signaling pathway
|
GO_0070431 |
[The series of molecular signals initiated by the binding of a ligand (such as a bacterial peptidoglycan) to a cytoplasmic nucleotide-binding oligomerization domain containing 2 (NOD2) protein receptor, and ending with regulation of a downstream cellular process.] |
|
nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway
|
GO_0035872 |
[The series of molecular signals initiated by a ligand binding to a nucleotide-binding domain, leucine rich repeat containing receptor (NLR), and ending with the regulation of a downstream cellular process. NLRs are cytoplasmic receptors defined by their tripartite domain architecture that contains: a variable C-terminus, a middle nucleotide-binding domain, and a LRR domain that is variable in the repeats composition and number.] |
|
regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway
|
GO_0070432 |
[Any process that modulates the frequency, rate, or extent of the nucleotide-binding oligomerization domain containing 2 (NOD2) pathway.] |
|
regulation of nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway
|
GO_0070424 |
[Any process that modulates the frequency, rate, or extent of a nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway (NLR) pathway.] |
|
negative regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway
|
GO_0070433 |
[Any process that stops, prevents, or reduces the frequency, rate, or extent of the nucleotide-binding oligomerization domain containing 2 (NOD2) pathway.] |